The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).

Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.

Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016

Board Intentions to apply for long-term fund-raising plan

Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders' Meeting

Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”

OBI Pharma announces the end of the implementation for its first treasury share buyback program